https://altradx.com/blog/ 2024-03-04T16:55:33+00:00 https://altradx.com/the-frequency-of-tay-sachs-disease-causing-mutations-in-the-brazilian-jewish-population-justifies-a-carrier-screening-program/ 2023-12-06T17:21:36+00:00 https://altradx.com/wp-content/uploads/2023/12/articulo_0002_Layer-2.jpg https://altradx.com/worldwide-live-births-following-the-transfer-of-chromosomally-abnormal-embryos-after-pgt-a-results-of-a-worldwide-web-based-survey/ 2023-12-06T17:26:23+00:00 https://altradx.com/wp-content/uploads/2023/12/articulo_0000_Layer-4.jpg https://altradx.com/the-pros-and-cons-of-preimplantation-genetic-testing-for-aneuploidy-clinical-and-laboratory-perspectives/ 2023-12-06T19:51:09+00:00 https://altradx.com/wp-content/uploads/2023/12/articulo_0001_Layer-3.jpg https://altradx.com/preimplantation-genetic-diagnosis-pgd-and-genetic-testing-for-aneuploidy-pgt-a-status-and-future-challenges/ 2023-12-13T17:28:43+00:00 https://altradx.com/wp-content/uploads/2023/12/articulo_0003_Layer-1.jpg https://altradx.com/validation-of-a-single-nucleotide-polymorphism-based-non-invasive-prenatal-test-in-twin-gestations-determination-of-zygosity-individual-fetal-sex-and-fetal-aneuploidy/ 2023-12-19T04:21:47+00:00 https://altradx.com/position-statement-from-the-chromosome-abnormality-screening-committee-on-behalf-of-the-board-of-the-international-society-for-prenatal-diagnosis/ 2023-12-19T04:24:25+00:00 https://altradx.com/expanding-the-indications-for-cell-free-dna-in-the-maternal-circulation-clinical-considerations-and-implications/ 2023-12-19T04:29:02+00:00 https://altradx.com/more-research-is-needed-prior-to-the-implementation-of-genome-wide-cell-free-dna-testing-in-specific-populations-response-to-letter-l19-020a-confined-placental-trisomy-detection-through-cell-free-dn/ 2023-12-19T04:31:51+00:00 https://altradx.com/screening-for-fetal-chromosomal-abnormalities/ 2023-12-19T04:36:02+00:00 https://altradx.com/noninvasive-prenatal-screening-for-fetal-aneuploidy-2016-update-a-position-statement-of-the-american-college-of-medical-genetics-and-genomics/ 2023-12-19T04:37:41+00:00 https://altradx.com/noninvasive-prenatal-screening-nips-for-fetal-chromosome-abnormalities-in-a-general-risk-population-an-evidence-based-clinical-guideline-of-the-american-college-of-medical-genetics-and-genomics-ac/ 2023-12-19T04:40:15+00:00 https://altradx.com/cell%e2%80%90free-dna-fetal-fraction-in-twin-gestations-in-single%e2%80%90nucleotide-polymorphism%e2%80%90based-noninvasive-prenatal-screening/ 2023-12-19T04:43:37+00:00 https://altradx.com/international-society-for-prenatal-diagnosis-ispd-position-statement-cell-free-cfdna-screening-for-down-syndrome-in-multiple-pregnancies/ 2023-12-19T04:45:43+00:00 https://altradx.com/quality-assurance-of-non-invasive-prenatal-screening-nips-for-fetal-aneuploidy-using-positive-predictive-values-as-outcome-measures/ 2023-12-19T04:47:53+00:00 https://altradx.com/cell-free-dna-screening-for-trisomies-21-18-and-13-in-pregnancies-at-low-and-high-risk-for-aneuploidy-with-genetic-confirmation/ 2023-12-19T04:50:05+00:00 https://altradx.com/cell-free-dna-screening-for-prenatal-detection-of-22q11-2-deletion-syndrome/ 2023-12-19T04:51:25+00:00 https://altradx.com/reproductive-carrier-screening-results-with-maternal-health-implications-during-pregnancy/ 2024-02-21T14:42:23+00:00 https://altradx.com/assessment-of-an-automated-approach-for-variant-interpretation-in-screening-for-monogenic-disorders-a-single-center-study/ 2024-02-21T17:28:41+00:00 https://altradx.com/the-association-of-hbb-related-significant-hemoglobinopathies-and-low-fetal-fraction-on-noninvasive-prenatal-screening-for-fetal-aneuploidy/ 2024-02-21T17:28:48+00:00 https://altradx.com/cost-effectiveness-of-genetic-and-clinical-predictors-for-choosing-combined-psychotherapy-and-pharmacotherapy-in-major-depression/ 2024-02-23T19:31:48+00:00 https://altradx.com/effect-of-pharmacogenetic-based-decision-support-tools-in-improving-depression-outcomes-a-systematic-review/ 2024-02-23T19:41:37+00:00 https://altradx.com/pharmacogenetics-in-psychiatry-an-update-on-clinical-usability/ 2024-02-23T19:42:24+00:00 https://altradx.com/cost-effectiveness-of-combinatorial-pharmacogenomic-testing-for-depression-from-the-canadian-public-payer-perspective/ 2024-02-23T19:42:58+00:00 https://altradx.com/pharmacogenetic-tests-and-depressive-symptom-remission-a-meta-analysis-of-randomized-controlled-trials/ 2024-02-23T19:52:16+00:00 https://altradx.com/the-clinical-utility-of-combinatorial-pharmacogenomic-testing-for-patients-with-depression-a-meta-analysis/ 2024-02-23T20:00:55+00:00 https://altradx.com/combinatorial-pharmacogenomic-testing-improves-outcomesfor-older-adults-withdepression/ 2024-02-23T20:10:32+00:00 https://altradx.com/impact-of-pharmacogenomics-on-clinical-outcomes-in-major-depressive-disorder-in-the-guided-trial-a-large-patient-and-rater-blinded-randomized-controlled-study/ 2024-02-23T20:18:02+00:00 https://altradx.com/efficacy-of-prospective-pharmacogenetic-testing-in-the-treatment-of-major-depressive-disorder-results-of-a-randomized-double-blind-clinical-trial/ 2024-02-23T20:22:01+00:00 https://altradx.com/the-effect-of-pharmacogenomic-testing-on-response-and-remission-rates-in-the-acute-treatment-of-major-depressive-disorder-a-meta-analysis/ 2024-02-23T20:23:47+00:00 https://altradx.com/improved-antidepressant-remission-in-major-depression-via-a-pharmacokinetic-pathway-polygene-pharmacogenetic-report/ 2024-02-23T20:25:45+00:00 https://altradx.com/prueba-farmacogenomica-para-pacientes-con-trastorno-del-espectro-autista-cuales-son-las-ventajas/ 2024-02-23T20:34:05+00:00 https://altradx.com/microbiota-in-health-and-diseases/ 2024-03-04T16:50:02+00:00 https://altradx.com/vaginal-microbiome-normalcy-vs-dysbiosis/ 2024-03-04T16:52:07+00:00 https://altradx.com/crosstalk-between-vaginal-microbiome-and-female-health-a-review/ 2024-03-04T16:53:24+00:00 https://altradx.com/effect-of-the-vaginal-microbiome-on-the-pregnancy-rate-in-women-receiving-assisted-reproductive-treatment/ 2024-03-04T16:55:33+00:00